tiprankstipranks
Advertisement
Advertisement

CRIS Stock Latest News

Curis announces pricing of $5.6M public offering
The FlyCuris announces pricing of $5.6M public offering
8d ago
CRIS
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks
PremiumCompany Announcements
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks
9d ago
CRIS
Curis files to sell 3.73M shares of common stock, warrants
PremiumThe Fly
Curis files to sell 3.73M shares of common stock, warrants
15d ago
CRIS
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring
PremiumCompany Announcements
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring
26d ago
8K
CRIS
Curis doses first five patients in TakeAim CLL study
PremiumThe Fly
Curis doses first five patients in TakeAim CLL study
26d ago
CRIS
Is CRIS a Buy, Before Earnings?
PremiumPre-EarningsIs CRIS a Buy, Before Earnings?
28d ago
CRIS
Curis price target raised to $43 from $17 at H.C. Wainwright
Premium
The Fly
Curis price target raised to $43 from $17 at H.C. Wainwright
1M ago
CRIS
Curis to report clinical data in the TakeAim Lymphoma study
Premium
The Fly
Curis to report clinical data in the TakeAim Lymphoma study
1M ago
CRIS
Curis consents first six patients in TakeAim CLL study
PremiumThe Fly
Curis consents first six patients in TakeAim CLL study
2M ago
CRIS
Upcoming Stock Splits This Week (July 6 to July 10) – Stay Invested
PremiumMarket News
Upcoming Stock Splits This Week (July 6 to July 10) – Stay Invested
2M ago
JZ
SVC
Curis trading halted, news pending
PremiumThe Fly
Curis trading halted, news pending
2M ago
CRIS
Curis Implements 1-for-20 Reverse Stock Split
PremiumCompany Announcements
Curis Implements 1-for-20 Reverse Stock Split
2M ago
8K
CRIS
Curis Stockholders Approve 1-for-20 Reverse Split
PremiumCompany AnnouncementsCuris Stockholders Approve 1-for-20 Reverse Split
2M ago
8K
CRIS
Analyst Reiterates Buy on Curis, Maintains $17 Price Target Amid Progress in TakeAim CLL Trial and Nasdaq Compliance Steps
Premium
Ratings
Analyst Reiterates Buy on Curis, Maintains $17 Price Target Amid Progress in TakeAim CLL Trial and Nasdaq Compliance Steps
2M ago
CRIS
Curis announces eleven active clinical sites in TakeAim CLL study
Premium
The Fly
Curis announces eleven active clinical sites in TakeAim CLL study
2M ago
CRIS
Curis Shareholders Approve Flexible Reverse Stock Split Authorization
PremiumCompany Announcements
Curis Shareholders Approve Flexible Reverse Stock Split Authorization
2M ago
8K
CRIS
Curis Shareholders Approve Expanded Capital Structure and Governance
PremiumCompany Announcements
Curis Shareholders Approve Expanded Capital Structure and Governance
3M ago
8K
CRIS
Why Is Vanguard Total Stock Market (VTI) ETF Falling Today, 5/15/26?
PremiumMarket News
Why Is Vanguard Total Stock Market (VTI) ETF Falling Today, 5/15/26?
3M ago
VTI
AAPL
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/14/26?
PremiumMarket News
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/14/26?
3M ago
VTI
AAPL
Curis Inc. Earnings Call Highlights Clinical Momentum
PremiumCompany AnnouncementsCuris Inc. Earnings Call Highlights Clinical Momentum
3M ago
CRIS
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/13/26?
Premium
Market News
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/13/26?
3M ago
AGL
VTI
Curis Reaffirmed at Buy as Analyst Maintains $5 Price Target on Emavusertib Clinical Catalysts in CLL and PCNSL
Premium
Ratings
Curis Reaffirmed at Buy as Analyst Maintains $5 Price Target on Emavusertib Clinical Catalysts in CLL and PCNSL
3M ago
CRIS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >